Kaneda Marisa, Oyama Manami, Yoshimi Takashi, Michihara Seiwa, Han Li-Kun, Fujita Nina, Takahashi Ryuji
Kampo Research Laboratories, Kracie Pharma, Ltd., 3-1 Kanebo-machi, Takaoka-shi, Toyama 933-0856, Japan.
Evid Based Complement Alternat Med. 2023 Aug 2;2023:8657478. doi: 10.1155/2023/8657478. eCollection 2023.
Ninjin'yoeito (NYT) is widely used clinically for the management of patients with frailty and other multiple symptoms. NYT is often administered with other drugs; however, little information is available on its drug interactions. Previous studies using human liver microsomes have reported that constituents of NYT either inhibit (schisandra fruit, cinnamon bark, glycyrrhiza, and poria sclerotium) or induce (schisandra fruit and glycyrrhiza) CYP3A4 expression. Herein, we conducted in vitro and in vivo studies targeting human CYP3A and mouse CYP3A to elucidate the effects of NYT coadministration with other drugs on hepatic drug metabolism. In an inhibition study using human liver microsomes, NYT showed concentration-dependent reversible inhibition and time-dependent inhibition. Furthermore, in an induction study using frozen human hepatocytes, the addition of 0.01-0.1 mg/mL NYT resulted in a concentration-dependent increase in CYP3A gene expression. Contrarily, no significant changes in CYP3A substrate blood concentrations were observed between untreated mice and mice that received either a single dose of NYT or repeated doses for 15 days. These results demonstrate that NYT has inhibitory and inductive effects on hepatic CYP3A in vitro, but orally administered NYT does not affect drug metabolism mediated by hepatic CYP3A in vivo in the mouse model. Although there is a little information about drug interactions of NYT, this study provides new evidence for that.
人参养荣汤(NYT)在临床上广泛用于治疗虚弱及其他多种症状的患者。NYT常与其他药物联合使用;然而,关于其药物相互作用的信息却很少。此前使用人肝微粒体的研究报告称,NYT的成分要么抑制(五味子果实、肉桂皮、甘草和茯苓)要么诱导(五味子果实和甘草)CYP3A4表达。在此,我们针对人CYP3A和小鼠CYP3A进行了体外和体内研究,以阐明NYT与其他药物联合使用对肝脏药物代谢的影响。在一项使用人肝微粒体的抑制研究中,NYT表现出浓度依赖性可逆抑制和时间依赖性抑制。此外,在一项使用冷冻人肝细胞的诱导研究中,添加0.01 - 0.1mg/mL的NYT导致CYP3A基因表达呈浓度依赖性增加。相反,在未处理的小鼠与接受单剂量NYT或重复给药15天的小鼠之间,未观察到CYP3A底物血药浓度有显著变化。这些结果表明,NYT在体外对肝脏CYP3A具有抑制和诱导作用,但在小鼠模型中,口服NYT在体内不影响肝脏CYP3A介导的药物代谢。尽管关于NYT药物相互作用的信息很少,但本研究为此提供了新的证据。